/
IMVT
$38.40-$0.34 (-0.88%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$8.0B
205M shares
52-week range
$14.32 – $39.28
96% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.27%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$27.14
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $21.0K | $0 | $0 | $0 | $0 | $0 | $409.0K |
| Gross profit | $0 | −$21.0K | $0 | $0 | $0 | $0 | $0 | −$409.0K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $25.7M | $47.9M | $68.6M | $101.8M | $160.3M | $212.9M | $360.9M | $456.7M |
| Operating income | −$450 | −$59.7M | −$108.1M | −$156.0M | −$208.3M | −$270.2M | −$438.2M | −$532.9M |
| EBITDA | $9.6K | −$65.6M | −$108.1M | −$156.7M | −$198.3M | −$258.5M | −$412.6M | −$505.0M |
| Net income | −$448 | −$66.4M | −$107.4M | −$156.7M | −$211.0M | −$259.3M | −$413.8M | −$505.6M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.00 | -1.54 | -1.22 | -1.43 | -1.71 | -1.88 | -2.73 | -2.77 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $7M | $-2.62 | $-2.99–$-2.43 | 9 |
| 2028 | $85M | $-2.54 | $-2.78–$-2.31 | 8 |
| 2029 | $450M | $-1.47 | $-2.97–$-0.02 | 9 |
| 2030 | $1.0B | $0.59 | $0.59–$0.59 | 3 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$4.93
Price
$38.40
Implied downside
-87%
Peer comparison
Immunovant, Inc. Common Stock
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
www.immunovant.com- Employees
- 315
- IPO / List date
- Jun 21, 2019
- HQ
- DURHAM, NC
Held by traders on TradeandTell
No one on the platform currently holds IMVT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 192,500 | $4.8M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IMVT yet.
